Technology

AR Optics: IDTechEx Explores Insights from IDTechEx at CES 2024

Published

2 years ago

February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ — Apple’s Vision Pro has recently grabbed all the headlines in the spatial computing world, following years of hype and rumors of Apple bringing a headset to market. The Vision Pro is thought to be merely the opening salvo of the tech giant’s strategy, with see-through augmented reality (AR) devices expected to be the endgame. Compared to the camera passthrough used in headsets like the Vision Pro and Meta’s Quest 3, this would vastly improve the view of the real world while helping to make devices much more like normal glasses – not to mention aiding social acceptability by making the wearer’s eyes visible to those around them.

As outlined in IDTechEx’s report, “Optics for Virtual, Augmented and Mixed Reality 2024-2034: Technologies, Players and Markets“, the development of optical combiners, specialized optical components which project virtual information on top of the real world, is a key hurdle holding back see-through AR from primetime. However, startling progress is being made to solve this, with CES 2024 giving a great overview of recent developments in AR optics and spatial computing overall.

Contrasting approaches to AR

The two biggest AR headset announcements at this year’s CES took very different approaches. TCL’s upcoming RayNeo X2 Lite headset fell under the banner of “lite AR”. These devices are lightweight with a glasses form factor, focusing on being minimally intrusive while displaying simple contextual information like directions or sports statistics to the wearer. In contrast, XReal’s Air 2 Ultra is more of a spiritual successor to the HoloLens, focusing on adding emphasis on mixed reality features like spatial localization and mapping, and hand tracking to XReal’s device lineup. While no heavyweight at 80g, it is not designed to be worn as an accessory in the same vein as “lite AR” devices.

Polymer waveguides showed impressive performance

Optics for lite AR were a fruitful space for innovation at this year’s CES. Chinese player Mojie, also known as Meta-Bounds, supplies Oppo its AR optics. It showed IDTechEx its newest resin surface relief diffractive waveguides at the event. Compared to the optical glass substrates more commonly used in AR waveguides, polymers can increase durability while reducing weight due to their lower density and potential elimination of the requirement for cover glass. They could also cut the cost of these specialized optical components. A major downside is that their lower refractive index limits the field of view of the waveguide, but this is not an issue for lite AR. Critically, Mojie’s waveguides can be bonded directly to ophthalmic lenses, meaning AR glasses can become viable prescription eyewear without clunky solutions like prescription inserts.

Shenzhen-based Optiark’s pre-production LHASA-5 resin waveguides could make lite AR even lighter: one waveguide, weighing only 4g, uses a single display to project images to both eyes. This could solve the comfort issues some face while wearing glasses with a monocular display without adding significant weight or cost. Optiark said it expects the image quality to surpass others already producing resin waveguides: this could be due to the multi-level diffraction gratings it employs, or it may be able to achieve higher new levels of surface flatness than are typical in polymer AR optics.

A new challenger to birdbath optics

Innovation was not limited to the lite AR space, with Korean player LetinAR’s latest optics looking like strong competitors to the birdbath optics used in lower-cost, wide field-of-view AR devices like those from XReal. This special class of reflective waveguide uses the proprietary PinTILT™ architecture, which allows a relatively affordable and high-resolution micro-OLED display to be used, just like with birdbath optics but unlike with most other waveguides. Although the design makes them thicker than other waveguides, it also allows these injection-molded plastic optics to have a wide FoV, making them suitable for immersive applications. Crucially, the wearer’s view of the real world and the view of the user’s eyes are vastly better than with birdbath optics. LetinAR’s optics are close to mass production readiness and were shown at CES in devices from Jorjin, Sharp, and Nimo.

Optics are taking AR headsets close to primetime readiness

Compared to previous years, AR felt significantly closer to mass-market viability at this year’s CES, with the contribution of optics being hard to understate here. Improved optical designs, in conjunction with the wider availability of emerging display technologies like micro-LED, are shrinking AR glasses down, with more efficient optical systems reducing demands on batteries and thermal management systems. Vuzix’s Z100 lite AR glasses, announced at CES, weigh less than many prescription glasses and quote a battery life of over 48 hours, with a Jade Bird Display micro-LED screen and advancement in waveguide design being key here. More immersive devices might not be quite so unobtrusive, but XReal’s Air 2 Ultra offers true MR features at $2,800 cheaper than the Vision Pro (although you will need to pair them with a high-end smartphone). Overall, the future for AR looks bright.

Further insight

The stories presented here provide only a small portion of IDTechEx’s insights from CES 2024, which are available to their subscribers, amongst much more timely information on emerging technologies on their portal. Events like CES help shape IDTechEx’s coverage of spatial computing with its recent reports, “Optics for Virtual, Augmented and Mixed Reality 2024-2034: Technologies, Players and Markets” and “Displays for Virtual, Augmented and Mixed Reality 2024-2034: Forecasts, Technologies, Markets“, giving comprehensive intelligence including 10 year granular adoption forecasts into these two critical technology markets.

About IDTechEx

IDTechEx guides your strategic business decisions through its Research, Subscription and Consultancy products, helping you profit from emerging technologies. For more information, contact research@IDTechEx.com or visit www.IDTechEx.com.

Images download:
https://www.dropbox.com/scl/fo/am175geqepdqx4arlkajv/h?rlkey=joekovb3od1kwo9amaxdrbx6y&dl=0

Media Contact:

Lucy Rogers
Sales and Marketing Administrator
press@IDTechEx.com
+44(0)1223 812300

Social Media Links:

Twitter: www.twitter.com/IDTechEx
LinkedIn: www.linkedin.com/company/IDTechEx

Photo – https://mma.prnewswire.com/media/2338554/IDTechEx_CES_2024.jpg
Logo – https://mma.prnewswire.com/media/478371/IDTechEx_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ar-optics-idtechex-explores-insights-from-idtechex-at-ces-2024-302059571.html

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

22 minutes ago

April 23, 2026

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

22 minutes ago

April 23, 2026

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

22 minutes ago

April 23, 2026

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system, helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company